Home/AI Suite/Evaluating Denial Prediction Tools

Buyer guide · 10 questions · ROI template · vendor-neutral

How to evaluate denial prediction tools. What CFOs miss.

Most healthcare leaders buying a denial prediction tool think they are buying predictive AI. Often they are buying a smarter scrubber with a probability badge on the output. Three things look similar on a demo and are wildly different in production: clearinghouse edits, pattern AI, and true predictive analytics. This page is the buyer scorecard. Ten questions, a calibration curve crash course, and an ROI math template you can hand to your CFO.

Get the buyer scorecard → Skip to 10 questions

Vendor-neutral framework Calibration curve question included Worked ROI example, transparent math

The category confusion

Pattern AI is not a smarter scrubber.

Clearinghouse edits are rule-based. A scrubber checks the claim against a known edit library: CCI edits, payer-specific format rules, modifier requirements, missing data fields. If a 99213 needs a modifier 25 when paired with a procedure, the scrubber catches that. If the place-of-service field is empty, the scrubber catches that. The edit library is finite, deterministic, and largely the same across vendors.

Pattern AI predicts denial probability from features. A real model takes payer, provider, code combinations, demographics, place of service, prior history with the same payer-CPT pair, and outputs a probability. The features are weighted by what actually correlated with denials in training data. The model catches things the edit library cannot: medical necessity denials, frequency-limit hits, payer-specific policy interpretations, and the soft denials that come back as CARC 50, CARC 96, or CARC 197 even though the claim was technically clean.

Most vendors selling "denial prediction" today are 80 percent clearinghouse edits with a probability score bolted on. Real predictive AI uses payer-specific feature engineering, learns from your denial history, and produces calibrated probabilities you can act on with confidence. The distinction matters because the price tag is 3x to 5x higher and the implementation effort is 6 months instead of 6 weeks. Buying the wrong category is the most common error CFOs make in this market.

What it usually is

Smarter scrubber.

Rule-based edit library applied pre-submission
Output: claim passes or fails specific edits
Probability score is heuristic, not a calibrated ML output
Same library across all customers, refreshed quarterly
Catches missing modifiers, format errors, CCI conflicts
Cannot predict medical necessity or frequency denials
Implementation: 4 to 8 weeks

What it should be

True predictive AI.

ML model trained on your denial history with payer features
Output: calibrated probability plus predicted CARC code
Features include payer, provider, code mix, demographics, prior history
Retrained at minimum quarterly, ideally on policy-change triggers
Catches denials clearinghouse edits cannot see
Reports calibration curve and per-payer precision
Implementation: 4 to 6 months to stable baseline

The buyer scorecard

Ten questions every vendor demo should answer.

If a vendor cannot answer eight of these ten with specifics, you are not buying predictive AI. You are buying marketing. Bring this list to the demo. Score each answer 0, 1, or 2. Pass the threshold at 14.

Is the model trained on my denial history or a generic claims dataset?

A model trained on generic claims data will be wrong on your payer mix, your provider mix, and your specialty. Demand training on at least 6 months of your own remits. If the vendor pools data across customers, demand transparency on the pool composition.

Why it matters · Foundation

What is your calibration curve on hold-out data?

When the model says 70 percent denial probability, is the actual denial rate 70 percent? Or is it 45 percent (overconfident) or 88 percent (underconfident)? This is the single most important diagnostic and most vendors will not have a ready answer.

Why it matters · Trust the output

How often do you retrain, and what triggers it?

Payer policies shift quarterly at minimum. Major payers push monthly policy bulletins. A model retrained annually is stale 75 percent of the time you pay for it. Look for quarterly retraining plus policy-change triggered off-cycle retraining on major payer updates and NCD/LCD changes.

Why it matters · Avoid drift

What features go into the model?

Minimum acceptable: payer, plan type, place of service, primary and secondary diagnoses, CPT/HCPCS, modifiers, provider, prior denial history for the same payer-CPT pair. If features stop at payer and CPT, this is a lookup table dressed as ML.

Why it matters · Predictive power

Can it predict the specific CARC denial reason, not just yes/no?

"Denied or not" is a binary classifier. Useful but limited. The interventions for CARC 50 (medical necessity) and CARC 197 (precertification missing) are completely different. A model that predicts the specific CARC enables targeted intervention; a binary model just flags risk.

Why it matters · Workflow precision

How does it integrate pre-submission with my workflow?

The score is worthless if it arrives after submission. Demand integration via API into the claim creation workflow or as a clearinghouse pre-submission filter. Validate latency: scoring 10,000 claims in batch is one architecture, scoring each claim under 500 milliseconds is another.

Why it matters · Actionability

What is the false positive rate at your recommended threshold?

A model that flags 40 percent of claims as high-risk is unworkable; the workflow team drowns. Demand precision and recall at the recommended threshold. Acceptable: precision 0.55 to 0.70, flagging 8 to 15 percent of claims. Anything higher than 15 percent flag rate burns staff time on false positives.

Why it matters · Staff time

Do you predict overturn probability on already-denied claims?

Pre-submission prediction is half the value. The other half is appeal triage on claims that came back denied via 835 remit. A good model ranks denied claims by overturn probability and expected dollar recovery, so the AR team works the highest-yield queue first.

Why it matters · Recovery yield

What is the ROI math and how is it measured?

Demand the formula in writing: intervention rate, catch rate at threshold, average claim value, overturn rate on caught denials. Demand the measurement plan: control group or pre-period baseline, 60 to 90 day attribution window, CARC-coded denial reduction in targeted categories on 835 remits.

Why it matters · CFO defense

Who owns the trained model at contract end?

The model trained on your denial history is an asset. If the vendor owns it exclusively, you have no continuity and no portability. Demand contract language giving you, at minimum, the trained model weights or an equivalent rebuild dataset at termination.

Why it matters · Exit risk

The CFO conversation

ROI math. The worked example.

Most vendor ROI claims survive zero minutes of CFO scrutiny because they collapse two distinct numbers into one. There is the dollar value of claims flagged (large, impressive) and the dollar value of denials actually prevented (smaller, real). The second is what your CFO will fund. Use this template to force the math into the open.

The worked example to the right uses conservative assumptions for a mid-size practice: 10,000 claims per month, 11 percent baseline denial rate, average claim value of $185. The model flags 12 percent of claims as high-risk. At the recommended threshold, precision is 0.62 (62 percent of flagged claims would actually have been denied without intervention). The workflow team successfully intervenes on 70 percent of flagged claims pre-submission. Of those, 80 percent of the predicted denials are prevented.

Net of intervention staff cost, the math produces a real recovered-revenue number per month. Demand the vendor populate this template with their numbers and verify the inputs against your own claim file. Anyone who refuses to share the input assumptions is selling vibes, not value.

ROI worked example · per month · 10K claim volume

Monthly claim volumeInput

10,000

Baseline denial rateFrom 835 remits, last 6 mo

11%

Average claim valueAllowed, net

$185

Flag rate at thresholdClaims AI scores as high-risk

12%

Claims flagged per month10K × 12%

1,200

Precision at thresholdOf flagged, % that would denial

0.62

True-positive denials caught1,200 × 0.62

744

Intervention success rateWorkflow team fixes pre-submit

70%

Denials actually prevented744 × 0.70 × 0.80

417

Recovered revenue, gross417 × $185

$77,145

Intervention staff cost1,200 reviews × $4.50/claim

($5,400)

Net recovered revenue / month

$71,745

The question most buyers skip

What is your calibration curve?

AUC and accuracy are the metrics vendors lead with. They are easy to game and easy to overstate. The metric that actually predicts whether the tool will work in your workflow is the calibration curve. It plots predicted probability on the x-axis against actual denial rate on the y-axis, bucketed by probability decile.

A well-calibrated model produces a curve close to the diagonal. When the model says 70 percent, the actual denial rate in that bucket is roughly 70 percent. When it says 30 percent, the actual rate is roughly 30 percent. You can trust the threshold and set it confidently to match your workflow capacity.

An overconfident model produces predictions far higher than the actual rate. The model says 70 percent denial probability, the actual rate is 40 percent, the workflow team chases ghosts, and trust in the tool collapses inside 60 days. An underconfident model misses real denials because its 30 percent predictions correspond to a 55 percent actual rate.

Ask the question. Demand the curve. Plot it from hold-out data, not training data. If the vendor cannot produce one in 48 hours, the model is not production-ready, the calibration has never been checked, or the data science team is not staffed at the level the price tag implies.

Full disclosure

We are a vendor too.

This page is honest about that. ASP-RCM builds and operates a denial prevention engine inside our RCM stack. We sell it. If you are going to use this scorecard to evaluate the market, you should use it to evaluate us as well. Hold us to the same ten questions, the same calibration curve, and the same ROI math template. If we cannot answer them with specifics, the framework worked.

Our denial prevention product runs ML scoring at claim creation, predicts CARC codes per payer, and surfaces interventions through the AR workflow. It is trained on your denial history, retrained quarterly with payer policy triggers, and reports the calibration curve in the standard model documentation we hand to every CFO at implementation.

Two pages worth a look if you want the product story rather than the buyer-side framework: the denial prevention product page and our technical denial prediction architecture writeup. Both are written for the same skeptical buyer this page is written for.

See denial prevention product → Read the architecture →

Common buyer questions

Frequently asked questions: evaluating denial AI.

How is denial prediction different from claim scrubbing?

Claim scrubbing is rule-based. A scrubber checks the claim against a known edit library (CCI edits, payer-specific format rules, modifier requirements) and flags violations before submission. Denial prediction is probabilistic. A real prediction model takes the full claim context (payer, provider, code combination, demographics, prior denial history for similar claims) and outputs a probability that the claim will be denied, often with a specific predicted denial reason code (CARC). Scrubbing catches what is mechanically wrong. Prediction catches what is statistically likely to be denied even when nothing is mechanically wrong, such as medical necessity denials, frequency-limit hits, and payer-specific policy interpretations not captured in edit libraries.

What denial prediction accuracy is realistic?

For a well-trained payer-specific model on a sufficiently large denial history, expect AUC in the 0.80 to 0.88 range on hold-out data. Precision at the recommended threshold should sit between 0.55 and 0.70, recall between 0.45 and 0.65. Anyone quoting AUC above 0.95 is either overfitting, training and testing on the same data, or measuring something other than denial prediction (often confusing it with claim acceptance, which is a much easier prediction problem). Calibration matters more than headline accuracy. A 70 percent prediction should mean the claim is denied 70 percent of the time across all claims with that score.

How long does it take to see ROI on denial prediction tools?

If the tool is trained on your own denial history (not a generic claims model), expect 60 to 90 days to first measurable ROI, and 4 to 6 months to a stable baseline. The 60-day lag exists because the model needs time to surface enough flagged claims for the workflow team to intervene on, the interventions need time to land before submission, and the resulting denial pattern needs to show up in payer remits (typically 30 to 45 days after submission via X12 835 transactions). Vendors promising ROI within 30 days are usually counting scrubber-style upfront edits, not true prediction-driven interventions.

Should I pilot on historical claims or live claims?

Both, in that order. Historical claims first to validate that the model actually predicts your denial patterns. Pull the last 6 to 12 months of claims and their remit outcomes, hold out the most recent 60 days as the test set, train on the rest, and check the calibration curve and the per-payer precision. If that holds up, run a 90-day live pilot on a single payer or single service line. Measure the intervention rate, the resulting reduction in CARC-coded denials, and the lift in first-pass yield. Never trust a vendor demo on their data only. Their best-case payer mix is not yours.

What if my claim volume is too small for machine learning?

Below roughly 50,000 claims per year you cannot reliably train a payer-specific model. You have three honest options. First, use a vendor that pools data across similar practices in your specialty and payer mix (transparency on the pool composition matters). Second, accept that you are buying a sophisticated scrubber with a probability score and price it accordingly, not as a true predictive AI. Third, focus on the highest-frequency denial categories (typically eligibility, authorization, and medical necessity) and build manual workflow rules around those without paying for ML you cannot calibrate. The first option is best if you can verify the pool is genuinely representative.

Does denial prediction replace my clearinghouse?

No. Clearinghouses do edit-based scrubbing, X12 transaction translation, payer routing, and 835 remit consolidation. Denial prediction sits upstream of submission as an additional intervention layer. A good architecture runs claims through your clearinghouse edits first, then through the prediction model, then surfaces high-probability denials for manual intervention before final submission. The two are complementary, not substitutable. Any vendor positioning their prediction tool as a clearinghouse replacement is overstating its scope.

How do you handle payer-specific rules and policy changes?

The honest answer is retraining cadence. Payer policies shift quarterly at minimum, and major payers push policy bulletins monthly. A static prediction model degrades within 90 days of last training. Ask the vendor: how often do you retrain, do you retrain per payer or globally, how do you detect concept drift, and do you maintain a policy-change feed that triggers off-cycle retraining when a major payer updates a coverage policy or NCD/LCD changes. If the answer is annual retraining, the model will be stale most of the time you are paying for it.

How do I prove the ROI to my CFO?

Three numbers your CFO will actually believe. First, the dollar value of claims flagged and successfully intervened on (intervention rate times catch rate times average claim value). Second, the reduction in CARC-coded denials in the targeted categories on 835 remits 60 to 90 days after pilot start, attributable to interventions (you need a control group or a pre-period baseline). Third, the staff time reallocated from denial appeals to upstream intervention (denials prevented at $25 per claim cost less than denials worked at $150 per claim). Present those three with the underlying calculation visible. Skip vanity metrics like 'denial probability score distribution' that do not translate to recovered revenue.

Get the buyer scorecard. Free.

The full 10-question scorecard as a fillable PDF, the ROI math template as a working spreadsheet, and a calibration curve checklist you can hand to any vendor. A senior partner on the call to walk it through. No pitch unless you ask for one.

Get the buyer scorecard See our denial AI